Format
Sort by
Items per page

Send to

Choose Destination

Best matches for psilocybin:

Potential Therapeutic Effects of Psilocybin. Johnson MW et al. Neurotherapeutics. (2017)

Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. Dinis-Oliveira RJ et al. Drug Metab Rev. (2017)

Psilocybin--summary of knowledge and new perspectives. Tylš F et al. Eur Neuropsychopharmacol. (2014)

Search results

Items: 1 to 20 of 930

1.

Bis(4-acet-oxy-N,N-di-methyl-tryptammonium) fumarate: a new crystalline form of psilacetin, an alternative to psilocybin as a psilocin prodrug.

Chadeayne AR, Golen JA, Manke DR.

Acta Crystallogr E Crystallogr Commun. 2019 May 31;75(Pt 6):900-902. doi: 10.1107/S2056989019007370. eCollection 2019 Jun 1.

2.

Classical psychedelics for the treatment of depression and anxiety: A systematic review.

Muttoni S, Ardissino M, John C.

J Affect Disord. 2019 Jul 30;258:11-24. doi: 10.1016/j.jad.2019.07.076. [Epub ahead of print] Review.

PMID:
31382100
3.

Rapid-acting antidepressants.

Witkin JM, Martin AE, Golani LK, Xu NZ, Smith JL.

Adv Pharmacol. 2019;86:47-96. doi: 10.1016/bs.apha.2019.03.002. Epub 2019 Apr 24.

PMID:
31378256
4.

Microdosing psychedelics: More questions than answers? An overview and suggestions for future research.

Kuypers KP, Ng L, Erritzoe D, Knudsen GM, Nichols CD, Nichols DE, Pani L, Soula A, Nutt D.

J Psychopharmacol. 2019 Jul 14:269881119857204. doi: 10.1177/0269881119857204. [Epub ahead of print]

PMID:
31303095
5.

Psychedelic microdosing benefits and challenges: an empirical codebook.

Anderson T, Petranker R, Christopher A, Rosenbaum D, Weissman C, Dinh-Williams LA, Hui K, Hapke E.

Harm Reduct J. 2019 Jul 10;16(1):43. doi: 10.1186/s12954-019-0308-4.

6.

Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives.

Pallavicini C, Vilas MG, Villarreal M, Zamberlan F, Muthukumaraswamy S, Nutt D, Carhart-Harris R, Tagliazucchi E.

Neuroimage. 2019 Jun 24;200:281-291. doi: 10.1016/j.neuroimage.2019.06.053. [Epub ahead of print]

PMID:
31247301
7.

REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics.

Carhart-Harris RL, Friston KJ.

Pharmacol Rev. 2019 Jul;71(3):316-344. doi: 10.1124/pr.118.017160. Review.

8.

Replication and extension of a model predicting response to psilocybin.

Russ SL, Carhart-Harris RL, Maruyama G, Elliott MS.

Psychopharmacology (Berl). 2019 Jun 15. doi: 10.1007/s00213-019-05279-z. [Epub ahead of print]

PMID:
31203401
9.

Motives and Side-Effects of Microdosing With Psychedelics Among Users.

Hutten NRPW, Mason NL, Dolder PC, Kuypers KPC.

Int J Neuropsychopharmacol. 2019 Jul 1;22(7):426-434. doi: 10.1093/ijnp/pyz029.

10.

Enzymatic route toward 6-methylated baeocystin and psilocybin.

Fricke J, Sherwood A, Kargbo R, Orry A, Blei F, Naschberger A, Rupp B, Hoffmeister D.

Chembiochem. 2019 May 31. doi: 10.1002/cbic.201900358. [Epub ahead of print]

PMID:
31150155
11.

Psychedelic-assisted therapies: The past, and the need to move forward responsibly.

Gardner J, Carter A, O'Brien K, Seear K.

Int J Drug Policy. 2019 Aug;70:94-98. doi: 10.1016/j.drugpo.2019.05.019. Epub 2019 May 25.

PMID:
31136924
12.

The Past and Future of Psychedelic Science: An Introduction to This Issue.

Doblin RE, Christiansen M, Jerome L, Burge B.

J Psychoactive Drugs. 2019 Apr-Jun;51(2):93-97. doi: 10.1080/02791072.2019.1606472.

PMID:
31132970
13.

Dynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin.

Lord LD, Expert P, Atasoy S, Roseman L, Rapuano K, Lambiotte R, Nutt DJ, Deco G, Carhart-Harris RL, Kringelbach ML, Cabral J.

Neuroimage. 2019 Oct 1;199:127-142. doi: 10.1016/j.neuroimage.2019.05.060. Epub 2019 May 25.

PMID:
31132450
14.

Denver votes to decriminalise psilocybin mushrooms.

Webster P.

Lancet. 2019 May 18;393(10185):2023. doi: 10.1016/S0140-6736(19)31082-7. No abstract available.

PMID:
31106737
15.

Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat.

Jefsen O, Højgaard K, Christiansen SL, Elfving B, Nutt DJ, Wegener G, Müller HK.

Acta Neuropsychiatr. 2019 Aug;31(4):213-219. doi: 10.1017/neu.2019.15. Epub 2019 May 20.

PMID:
31106729
16.

Cessation and reduction in alcohol consumption and misuse after psychedelic use.

Garcia-Romeu A, Davis AK, Erowid F, Erowid E, Griffiths RR, Johnson MW.

J Psychopharmacol. 2019 May 14:269881119845793. doi: 10.1177/0269881119845793. [Epub ahead of print]

PMID:
31084460
17.

Narrative identity, rationality, and microdosing classic psychedelics.

Webb M, Copes H, Hendricks PS.

Int J Drug Policy. 2019 Aug;70:33-39. doi: 10.1016/j.drugpo.2019.04.013. Epub 2019 May 6.

PMID:
31071597
18.

Serotonergic hallucinogens and recognition of facial emotion expressions: a systematic review of the literature.

Rocha JM, Osório FL, Crippa JAS, Bouso JC, Rossi GN, Hallak JEC, Dos Santos RG.

Ther Adv Psychopharmacol. 2019 Apr 26;9:2045125319845774. doi: 10.1177/2045125319845774. eCollection 2019. Review.

19.

Psychedelics as a treatment for disorders of consciousness.

Scott G, Carhart-Harris RL.

Neurosci Conscious. 2019 Apr 21;2019(1):niz003. doi: 10.1093/nc/niz003. eCollection 2019.

20.

Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.

Griffiths RR, Hurwitz ES, Davis AK, Johnson MW, Jesse R.

PLoS One. 2019 Apr 23;14(4):e0214377. doi: 10.1371/journal.pone.0214377. eCollection 2019.

Supplemental Content

Loading ...
Support Center